This site is intended for healthcare professionals only
DiabetesontheNet Logo
Sign In / Register

Issue:

Share this article

Renal outcomes with SGLT2 versus DPP-4 inhibitors: CPRD data

SGLT2is are associated with a reduced risk of kidney disease progression and death compared with DPP-4is.

In 2020, the International Society of Nephrology agreed a consensus definition of clinical trial outcomes for kidney failure (Levin et al, 2020). The present retrospective cohort study sought to compare renal outcomes of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes according to these criteria. Using data from the UK Clinical Practice Research Database, 23,438 people initiating an SGLT2i were compared with those initiating a DPP-4i, matched 1:1 according to propensity score (factors including age, sex, frailty, and micro- and macrovascular complications).

The primary endpoint was a composite of ≥40% eGFR decline (confirmed by a second measurement over 28 days), end-stage renal disease (ESRD; itself a composite of kidney transplantation, maintenance of dialysis, sustained low eGFR <15 mL/min/1.73 m² or diagnosis of ESKD) or renal death. Over a median follow-up of 2.1 years, use of an SGLT2i was associated with a lower risk of the primary endpoint compared with a DPP-4i (7.5 vs 11.8 events per 1000 person-years; hazard ratio [HR], 0.64; 95% CI, 0.56–0.74).

Regarding individual outcomes, SGLT2i use was associated with reduced risk of all-cause mortality, eGFR decline and ESRD. A difference in all-cause mortality rates was only observed in people with a lower HbA1c (<53 mmol/mol) at baseline, whereas differences in renal outcomes appeared to be independent of glycaemic control.

Despite limitations, including the retrospective cohort design and potential selection bias due to the use of propensity scores, the authors conclude that SGLT2is are associated with a reduced risk of kidney disease progression and death compared with DPP-4is.

The study was funded by AstraZeneca.

Click here to read the study in full.

REFERENCES:

Levin A, Agarwal R, Herrington WG et al; International Society of Nephrology (2020) International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 98: 849–59

Idris I, Zhang R, Mamza JB et al (2022) Significant reduction in chronic kidney disease progression with sodium–glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: an observational outcomes study based on international guidelines for kidney disease. Diabetes Obes Metab 8 Jun [Epub ahead of print]. doi: 10.1111/dom.14799

Related content
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.